ImmuCell Corporation (NASDAQ: ICCC) is a Healthcare company (Biotechnology) with a market capitalization of $103M. The Maz Rating grades it against the other companies in its sector.
ImmuCell Corporation's current Maz Rating and its five factor grades are for members: log in to see them.
At $11.33, ImmuCell Corporation trades at 56.9x trailing earnings, 3.1x sales and 3.2x book value, with an EV/EBITDA of 24.0. Over the last twelve months it generated about $33M of revenue and $2M of net income. It runs a gross margin of 40.8%, an operating margin of 14.5% and a net margin of 5.7%. It shows return on equity of 6.2%, return on invested capital of 10.5% and a free cash flow yield of 5.2%. On the balance sheet: a debt-to-equity ratio of 0.37 and a current ratio of 4.61. Over the past 52 weeks the share price ranged from $4.52 to $12.10, with a beta of 0.62.
ImmuCell Corporation does not currently pay a dividend.
ImmuCell Corporation functions as an animal health enterprise, specializing in the creation, manufacturing, and commercialization of offerings aimed at improving the vitality and output of dairy and beef cattle, serving both the U.S. domestic market and international regions. Among its key products is First Defense, an orally administered preventative designed to combat scours in newborn dairy and beef calves. The company also provides Tri-Shield First Defense, a passive antibody treatment effective against E. coli, coronavirus, and rotavirus. Additionally, ImmuCell offers the California Mastitis Test, a diagnostic instrument used to quantify somatic cell counts in milk and identify which specific udder quarter may be affected by mastitis. Its Dual-Force First Defense product, incorporating a whey protein concentrate, caters to the nutritional and animal feed supplement industries. Currently under development is Re-Tain, a Nisin-based intramammary therapy targeting subclinical mastitis in lactating dairy cows. The company primarily distributes its products through a network of animal health distributors. ImmuCell Corporation was established in 1982 and is based in Portland, Maine.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
Yes. As of September 2026, ImmuCell Corporation (ICCC) is classified as HALAL by Maz Vantage: it passes all 5 published Shariah screening standards it was tested against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 8.62% / 30% · (Cash+Inv) / Mkt Cap (36m) 8.64% / 30% · Interest income / Revenue 0.87% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 8.62% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 8.64% / 33% · Receivables / Mkt Cap (36m) 3.73% / 49% · Interest income / Revenue 0.87% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 8.62% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 8.64% / 33.33% · Receivables / Mkt Cap (24m) 3.73% / 33.33% · Interest income / Revenue 0.87% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 18.8% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 15.1% / 33.33% · Receivables / Avg Assets (4Q) 6.86% / 33.33% · Interest income / Revenue 0.87% / 5% | Pass |
| FTSE | Debt / Total Assets 16.5% / 33.33% · (Cash+ST Inv) / Total Assets 16.5% / 33.33% · (Cash+Recv) / Total Assets 23.6% / 33.33% · Interest income / Revenue 0.87% / 5% | Pass |
Yes. As of September 2026, ImmuCell Corporation (ICCC) is classified as HALAL by Maz Vantage: it passes all 5 published Shariah screening standards it was tested against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
Yes. ImmuCell Corporation is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
About 0.87% of each dividend: ImmuCell Corporation's interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.